OLEMA PHARMACEUTICALS, INC. Increase (Decrease) in Other Current Liabilities
OLEMA PHARMACEUTICALS, INC. (OLMA) reported Increase (Decrease) in Other Current Liabilities of $9.34 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentLiabilities · last filed 2026-08-10
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in other current liabilities for the quarter ending 2026-06-30 was $8.03M, a 36.75% decline year-over-year.
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in other current liabilities for the quarter ending 2026-03-31 was $1.30M.
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in other current liabilities for the quarter ending 2025-12-31 was $3.63M, a 62.83% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in other current liabilities for the quarter ending 2025-09-30 was $5.90M, a 1.43% increase year-over-year.
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in other current liabilities for fiscal 2025 was $10.98M, a 1.95% decline from fiscal 2024.
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in other current liabilities for fiscal 2024 was $11.20M, a 279.99% increase from fiscal 2023.
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in other current liabilities for fiscal 2023 was $2.95M, a 57.99% decline from fiscal 2022.
- OLEMA PHARMACEUTICALS, INC. increase (decrease) in other current liabilities for fiscal 2022 was $7.02M, a 53.53% increase from fiscal 2021.
| Period end | Increase (Decrease) in Other Current Liabilities 3 month | Increase (Decrease) in Other Current Liabilities 6 month | Increase (Decrease) in Other Current Liabilities 9 month | Increase (Decrease) in Other Current Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $9.34M 10-Q · filed 2026-08-10 | $12.97M derived: sum of 3 quarters · filed 2026-08-10 | $18.87M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $1.30M 10-Q · filed 2026-05-12 | $4.93M derived: sum of 2 quarters · filed 2026-05-12 | $10.84M derived: sum of 3 quarters · filed 2026-05-12 | $23.54M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $3.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $9.53M derived: sum of 2 quarters · filed 2026-03-16 | $22.23M derived: sum of 3 quarters · filed 2026-08-10 | $10.98M 10-K · filed 2026-03-16 |
| 2025-09-30 | $5.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $18.60M derived: sum of 2 quarters · filed 2026-08-10 | $7.35M 10-Q · filed 2025-11-10 | $9.58M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $12.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.45M 10-Q · filed 2026-08-10 | $3.68M derived: sum of 3 quarters · filed 2026-08-10 | $9.50M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$11.25M 10-Q · filed 2026-05-12 | -$9.02M derived: sum of 2 quarters · filed 2026-05-12 | -$3.20M derived: sum of 3 quarters · filed 2026-05-12 | $358.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $8.05M derived: sum of 2 quarters · filed 2026-03-16 | $11.61M derived: sum of 3 quarters · filed 2026-03-16 | $11.20M 10-K · filed 2026-03-16 |
| 2024-09-30 | $5.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $9.38M derived: sum of 2 quarters · filed 2025-11-10 | $8.97M 10-Q · filed 2025-11-10 | $14.14M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $3.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $3.15M 10-Q · filed 2025-08-11 | $8.32M derived: sum of 3 quarters · filed 2025-08-11 | $8.79M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$404.00K 10-Q · filed 2025-05-13 | $4.77M derived: sum of 2 quarters · filed 2025-05-13 | $5.24M derived: sum of 3 quarters · filed 2025-05-13 | -$147.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $5.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $5.64M derived: sum of 2 quarters · filed 2025-03-18 | $257.00K derived: sum of 3 quarters · filed 2025-03-18 | $2.95M 10-K · filed 2025-03-18 |
| 2023-09-30 | $469.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$4.91M derived: sum of 2 quarters · filed 2024-11-12 | -$2.22M 10-Q · filed 2024-11-12 | $1.51M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$5.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$2.69M 10-Q · filed 2024-08-06 | $1.04M derived: sum of 3 quarters · filed 2024-08-06 | $2.41M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $2.69M 10-Q · filed 2024-05-08 | $6.43M derived: sum of 2 quarters · filed 2024-05-08 | $7.79M derived: sum of 3 quarters · filed 2024-05-08 | $9.82M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $3.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $5.10M derived: sum of 2 quarters · filed 2024-03-11 | $7.13M derived: sum of 3 quarters · filed 2024-03-11 | $7.02M 10-K · filed 2024-03-11 |
| 2022-09-30 | $1.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $3.39M derived: sum of 2 quarters · filed 2022-11-08 | $3.28M 10-Q · filed 2022-11-08 | $2.78M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-06-30 | $2.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.92M 10-Q · filed 2022-08-09 | $1.42M derived: sum of 3 quarters · filed 2023-05-09 | $2.59M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-03-31 | -$113.00K 10-Q · filed 2023-05-09 | -$612.00K derived: sum of 2 quarters · filed 2023-05-09 | $565.00K derived: sum of 3 quarters · filed 2023-05-09 | $3.45M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$499.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $678.00K derived: sum of 2 quarters · filed 2023-03-09 | $3.56M derived: sum of 3 quarters · filed 2023-03-09 | $4.57M 10-K · filed 2023-03-09 |
| 2021-09-30 | $1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $4.06M derived: sum of 2 quarters · filed 2022-11-08 | $5.07M 10-Q · filed 2022-11-08 | $5.93M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $2.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $3.89M 10-Q · filed 2022-08-09 | $4.75M derived: sum of 3 quarters · filed 2022-08-09 | $6.54M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $1.01M 10-Q · filed 2022-05-09 | $1.87M derived: sum of 2 quarters · filed 2022-05-09 | $3.66M derived: sum of 3 quarters · filed 2022-05-09 | $3.76M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $862.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $2.65M derived: sum of 2 quarters · filed 2022-02-28 | $2.75M derived: sum of 3 quarters · filed 2022-02-28 | $2.77M 10-K · filed 2022-02-28 |
| 2020-09-30 | $1.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.89M derived: sum of 2 quarters · filed 2021-11-10 | $1.91M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $97.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $125.00K 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $28.00K 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | $358.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |